Full-Time

IT Business Analyst

Updated on 7/21/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Dublin, Ireland

In Person

On-site in Dublin, Ireland at Northern Cross.

Category
Business & Strategy (1)
Required Skills
SAP Products

Get referred to Viatris

Find people who can refer or advise you

Requirements
  • Must understand overly complex technology projects and concepts as they relate to high-level business objectives, and ability to present those concepts to both IT and non-IT audiences in a concise and easily understandable manner.
  • Minimum of a bachelor’s degree (or equivalent) and minimum of 2 years of experience. However, a combination of experience and/or education will be taken into consideration.
  • Functional knowledge of the following SAP operations modules: Materials Management, Warehouse Management, Production Planning and Quality Management.
  • Ability to develop a tactical partnership with business customers.
  • Strong understanding of highly technical custom software solutions.
  • Ability to drive complex conceptual discussions and develop system requirements. This includes the ability to generate innovative ideas to resolve problems.
  • Excellent verbal and written communication skills and the ability to interact professionally with a diverse group of executives, managers, and subject matter experts.
  • Strong understanding of Manufacturing Operations Management (MOM) or Manufacturing Execution System (MES) applications.
  • Strong understanding of IT/OT applications’ System Development Life Cycle and related CSV activities.
Responsibilities
  • Understand Viatris’ business, pain points, needs, and strategic plans around manufacturing area.
  • Able to manage complex process analyses for all areas of operations within the site. Including manufacturing/packaging, quality, warehouse, and plant maintenance processes.
  • Facilitates process to gather requirements in support of efforts led by a Solutions Leader or Project Manager. Evaluates information gathered from multiple sources, reconciles conflicts, decomposes high-level information into details, differentiates between actual and required user needs.
  • Participates in global IT projects at a plant site, as well as in projects that are strictly local in nature.
  • Skilled in general business analysis and validation techniques. Elicits requirements using interviews, analysis of documents, requirements workshops, surveys, site visits, business process descriptions, use cases, scenarios, and workflow analysis and other relevant techniques, e.g., Value Stream Mapping.
  • Maintains current understanding of trends and issues in the IT industry, including current technologies in consideration by corporate IT.
  • Provides day-to-day support related to the installed application portfolio at a site. Collaborates with other IT teams to resolve day-to-day issues, as needed, such as the Run team.
  • Proactively connects, collaborates, and maintains communication with external and internal customers to analyze information needs and functional requirements and deliver project methodology artifacts as needed (following Viatris’ project methodology)
  • Provides support and/or direction to project and program manager(s) in overcoming hurdles and moving projects forward by proactively mitigating open issues and project risks. Maintains consistent communication channels between all vested parties (steering committee, business sponsors, IT stakeholders, project team, etc.). Supports organization change management efforts in areas of responsibility.
  • Acts as gate keeper/local system owner for Global applications installed at the site. Ensures GxP and SOX compliance as appropriate.
  • Function as a coordinator between SAP end users and the IT support organization, ensuring that business needs are fully documented and understood, and assist the IT organization in prioritizing requirements, developing, and testing solutions, and delivering enhanced SAP functionality to the business.
  • Play an active role in application integration implementations for EU sites

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA acceptance of meloxicam NDA on May 18, 2026 with PDUFA decision December 27, 2026.
  • Greater China revenue 9.8% growth in Q1 2026 driven by cardiovascular demand and e-commerce investments.
  • New product revenues $71 million in Q1 2026 from launches including XULANE LO and meloxicam pipeline.

What critics are saying

  • EpiPen market exclusivity loss late 2026 slashes $1.2B annual revenue with 40–50% margin erosion.
  • Indore facility FDA reinspection delay beyond Q1 2027 halts $900M capacity risking $120M quarterly loss.
  • Negative ROIC of –2.6% versus 8.2% WACC destroys $1.1B shareholder value annually with no recovery moat.

What makes Viatris unique

  • Unique first approved GAD treatment Effexor SR in Japan with 7.6% patient prevalence.
  • Only global portfolio combining branded drugs, generics, complex generics, biosimilars across 165 countries.
  • Fast acting meloxicam candidate targeting 80 million acute pain patients as non-opioid alternative in US.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.